#Weight loss drugs

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

The FDA will require new warnings across the entire GLP-1 drug class about a possible increased risk of NAION, a rare condition that damages the optic nerve and can cause permanent vision loss. The class includes Ozempic, Wegovy, Zepbound and Mounjaro. Because the drugs are widely used, the warning forces a difficult question: when a patient develops NAION, should treatment stop? Regulators in Europe and the U.S. have answered differently. An ophthalmologist who has asked patients about GLP-1 use for two years says the FDA should now study what happens after a diagnosis, and that patients cannot wait years for answers.